Profile data is unavailable for this security.
About the company
Ikena Oncology, Inc. is a targeted oncology company. The Company develops precision medicines tailored to biomarker-defined patient groups with specific unmet needs. The Company approach in each of its programs is to target both cancer-driving targets and mechanisms of resistance to other targeted therapies. The Company’s advanced targeted oncology program, IK-930, is a paralog-selective inhibitor of the transcriptional enhanced associate domain (TEAD). The TEAD transcription factors execute the ultimate step in the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted and chemo therapies. The Company’s first program in the RAS pathways, IK-595, is designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. In addition, it is also developing IK-175, an aryl hydrocarbon receptor (AHR) antagonist in collaboration with Bristol Myers Squibb.
- Revenue in USD (TTM)15.62m
- Net income in USD-68.77m
- Incorporated2016
- Employees80.00
- LocationIkena Oncology Inc50 Northern Ave.BOSTON 02210United StatesUSA
- Phone+1 (857) 343-8292
- Fax+1 (302) 655-5049
- Websitehttps://www.ikenaoncology.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paratek Pharmaceuticals Inc | 160.27m | -63.57m | 121.40m | 268.00 | -- | -- | -- | 0.7575 | -1.18 | -1.18 | 2.97 | -3.02 | 0.8994 | 1.67 | 2.88 | 598,014.90 | -35.67 | -42.62 | -44.19 | -48.16 | 85.61 | -- | -39.66 | -124.08 | 3.22 | -2.66 | 2.99 | -- | 23.13 | 66.26 | -7.59 | -- | -49.69 | -- |
| Aravive Inc | 9.14m | -76.32m | 123.88m | 23.00 | -- | 11.62 | -- | 13.56 | -2.20 | -2.20 | 0.2514 | 0.1781 | 0.1406 | -- | 154.86 | 397,260.90 | -117.47 | -65.90 | -169.82 | -75.91 | -- | -- | -835.31 | -847.43 | -- | -- | 0.00 | -- | 22.78 | -25.57 | -94.94 | -- | -69.69 | -- |
| Carisma Therapeutics Inc | 40.00m | -19.88m | 124.39m | 17.00 | -- | 3.96 | -- | 3.11 | -0.0991 | -0.0991 | 0.1991 | 0.7802 | 0.1861 | -- | 3.81 | 2,352,941.00 | -9.25 | -25.47 | -10.27 | -27.87 | -- | -- | -49.71 | -236.32 | -- | -- | 0.00 | -- | 50.69 | 148.16 | -5,817.86 | -- | -- | -- |
| Gracell Biotechnologies Inc (ADR) | 0.00 | -88.42m | 124.54m | 348.00 | -- | 0.6219 | -- | -- | -1.31 | -1.31 | 0.00 | 2.96 | 0.00 | -- | -- | -- | -32.69 | -- | -36.37 | -- | -- | -- | -- | -- | -- | -- | 0.1063 | -- | -100.00 | -- | -33.89 | -- | -- | -- |
| Mediwound Ltd | 26.50m | -19.60m | 125.63m | 73.00 | -- | 8.80 | -- | 4.74 | -3.85 | -3.85 | 5.32 | 1.51 | 0.7596 | 8.43 | 4.77 | 362,958.90 | -56.19 | -26.49 | -83.43 | -35.20 | 49.69 | 47.32 | -73.97 | -42.93 | 3.64 | -0.7467 | 0.0719 | -- | 11.50 | 60.39 | -44.63 | -- | -12.39 | -- |
| Galectin Therapeutics Inc | 0.00 | -38.87m | 128.95m | 12.00 | -- | -- | -- | -- | -0.6545 | -0.6545 | 0.00 | -0.5418 | 0.00 | -- | -- | 0.00 | -122.88 | -84.71 | -188.84 | -104.98 | -- | -- | -- | -- | -- | -90.45 | 5.22 | -- | -- | -- | -26.63 | -- | -- | -- |
| Invivyd Inc | 0.00 | -241.32m | 129.39m | 84.00 | -- | 0.363 | -- | -- | -2.23 | -2.23 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -48.11 | -- | -52.68 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.41 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -32.75m | 130.07m | 50.00 | -- | 0.8028 | -- | -- | -0.7433 | -0.7433 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -18.37 | -27.41 | -18.72 | -28.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 4.62 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 130.20m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Ikena Oncology Inc | 15.62m | -68.77m | 130.89m | 80.00 | -- | 0.8906 | -- | 8.38 | -1.90 | -1.90 | 0.4316 | 4.05 | 0.0744 | -- | -- | 195,225.00 | -32.73 | -- | -37.03 | -- | -- | -- | -440.29 | -- | -- | -- | 0.00 | -- | -49.59 | -- | -101.57 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 5.00m | -58.39m | 131.32m | 39.00 | -- | 1.98 | -- | 26.26 | -1.38 | -1.38 | 0.1178 | 1.94 | 0.0515 | -- | 5.90 | 128,205.10 | -60.09 | -43.13 | -64.37 | -45.68 | -- | -- | -1,167.76 | -1,148.11 | -- | -- | 0.00 | -- | -66.67 | -- | -36.25 | -- | 49.85 | -- |
| G1 Therapeutics Inc | 51.30m | -147.56m | 133.28m | 170.00 | -- | 1.93 | -- | 2.60 | -3.39 | -3.39 | 1.18 | 1.33 | 0.2321 | 0.3815 | 6.11 | 301,770.60 | -66.76 | -46.91 | -77.90 | -51.16 | 92.69 | -- | -287.63 | -470.79 | 4.59 | -14.06 | 0.5284 | -- | 62.98 | -- | 0.5345 | -- | 11.47 | -- |
| Puma Biotechnology Inc | 228.03m | 2.00k | 133.86m | 192.00 | -- | 6.16 | 15.00 | 0.587 | -0.0043 | -0.0043 | 5.10 | 0.4662 | 1.02 | 9.47 | 7.71 | 1,187,662.00 | 0.0009 | -24.02 | 0.0015 | -39.26 | 75.84 | 81.33 | 0.0009 | -22.63 | 1.67 | 2.20 | 0.8198 | -- | -9.92 | 52.46 | 100.01 | -- | -32.63 | -- |
| Anixa Biosciences Inc | 0.00 | -12.09m | 135.45m | 4.00 | -- | 4.87 | -- | -- | -0.3958 | -0.3958 | 0.00 | 0.8987 | 0.00 | -- | -- | 0.00 | -38.54 | -80.77 | -39.42 | -85.60 | -- | -- | -- | -3,362.83 | -- | -- | 0.00 | -- | -100.00 | -- | -4.95 | -- | -- | -- |
| Graphite Bio Inc | 0.00 | -101.05m | 140.17m | 120.00 | -- | 0.4736 | -- | -- | -1.84 | -1.84 | 0.00 | 5.09 | 0.00 | -- | -- | 0.00 | -27.92 | -- | -28.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -42.81 | -- | -- | -- |
Data as of Mar 31 2023. Currency figures normalised to Ikena Oncology Inc's reporting currency: US Dollar USD
41.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2022 | 3.72m | 10.27% |
| BVF Partners LPas of 31 Dec 2022 | 2.50m | 6.90% |
| Citadel Advisors LLCas of 31 Dec 2022 | 2.13m | 5.87% |
| CHI Advisors LLCas of 31 Dec 2022 | 1.64m | 4.52% |
| Verition Fund Management LLCas of 31 Dec 2022 | 1.58m | 4.36% |
| Invus Public Equities Advisors LLCas of 31 Dec 2022 | 1.55m | 4.27% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 975.79k | 2.69% |
| Laurion Capital Management LPas of 31 Dec 2022 | 529.00k | 1.46% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 300.79k | 0.83% |
| Geode Capital Management LLCas of 31 Dec 2022 | 236.43k | 0.65% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
